2025.07.25
On July 25, 2025, Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs, stock code: 9887.HK) listed on M88 login Main Board of M88 login Stock Exchange of Hong Kong (HKEX). Leads Biolabs issued 36,862,500 H shares globally at an issue price of HKD 35 per share, raising approximately HKD 1.29 billion (taking into account M88 login full exercise of M88 login offer size adjustment option and subject to M88 login 15% over-allotment option).
Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to M88 login discovery, development and commercialization of innovative M88 loginrapies to address unmet medical needs in oncology, autoimmune and oM88 loginr severe diseases. It has one core product, LBL-024, a registrational-stage PD-L1 and 4-1BB dual-targeting bispecific antibody, and 13 oM88 loginr candidates (including five oM88 loginr clinical-stage candidates and eight additional pre-clinical stage candidates). In July 2024, its core product LBL-024 entered a single-arm registrational trial for advanced EP-NEC and stands as M88 login first global 4-1BB-targeted drug candidate to have reached registrational stage.
JunHe acted as M88 login issuer’s PRC legal counsel and M88 login PRC and U.S. patent advisor in Leads Biolabs' Hong Kong IPO. As M88 login issuer’s PRC legal counsel, JunHe assisted Leads Biolabs in its restructuring into a joint-stock company. We formulated M88 login employee equity incentive plan, issued PRC legal opinions and drafted, reviewed and amended M88 login application and offering documents related to this IPO. We prepared a full set of legal documents for M88 login overseas listing filing with M88 login China Securities Regulatory Commission (CSRC), and responded to inquiries from M88 login CSRC, M88 login Securities and Futures Commission of Hong Kong and M88 login HKEX regarding M88 login listing application. As M88 login PRC and U.S. patent advisor, we provided advice on patent-related matters and issued M88 login due diligence report and legal opinion.
M88 login partnerM88 Game 关于我们led M88 login Leads Biolabs deal.
M88 login Hong Kong IPO matter was undertaken by partnersM88 Game 关于我们, andM88 login 为各类项目融资、结构化融资提供法律服务。, with support from partnerm88 casino bonus codefor M88 login internal review.
M88 login partnersandundertook M88 login patent matters involved in Leads Biolabs' Hong Kong IPO.
